← All Terns Pharmaceuticals, INC filings

Terns Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
TERN
Terns Pharmaceuticals, INC
10-K/A: Terns Pharmaceuticals Files 10-K/A for Governance Update
Terns Pharmaceuticals filed an amendment to its 2025 Annual Report to provide required Part III disclosures regarding executive compensation and corporate governance.
NASDAQ
TERN
Terns Pharmaceuticals, INC
10-K: Terns Pharmaceuticals Reports Full Year 2024 Results, Highlights Clinical Progress in Oncology and Obesity Programs
Terns Pharmaceuticals' 10-K filing summarizes the company's financial results for 2024 and provides updates on its clinical development programs, including TERN-701 for CML and TERN-601 for obesity.
NASDAQ
TERN
Terns Pharmaceuticals, INC
10-K: Terns Pharmaceuticals Outlines Capital Structure and Pipeline Progress in Annual Filing
Terns Pharmaceuticals' 10-K filing details its capital stock, registration rights, and progress in developing treatments for CML and obesity, with cash runway into 2026.